Dextera Surgical (DXTR) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 12

Dextera Surgical (DXTR) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 12 from a previous price target of $15 . Wedbush advised their investors in a research report released on Aug 10, 2016.

Dextera Surgical

Leave a Reply

Dextera Surgical - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dextera Surgical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.